Evidence-based therapy after stroke;Medikamentell terapi efter slaganfall bör vara evidensbaserad: Organisatoriska, ekonomiska och etiska avgöranden styr valet av behandling

Lakartidningen

Volumn 100, Issue 47, 2003, Pages 3860-3866

  Terént, Andreas ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; WARFARIN;

ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; SIDE EFFECT; STROKE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; DIURETICS; EVIDENCE-BASED MEDICINE; HEPARIN; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; WARFARIN;

EID: 0346887001     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. International Stroke Trial Collaborative Group. The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute stroke. Lancet 1997;349:1569-81.
2. Chinese Acute Stroke Trial Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischemic stroke. Lancet 1997;349:1641-9.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002;324:71-86.
4. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamol and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
5. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at high risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
6. Hankey G, Sudlow CLM, Dunbabin DW. Thienopyridine derivates (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software; 2002.
7. Chowdhury A, Ganguly G, Chowdhury D, Santra A, Gupta JD, Roy T. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective endoscopic study. Indian J Gastroenterol 2001;20:227-9.
8. Koudstaal PJ. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2002.
9. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
10. Segal JB, MacNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2002.
11. Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute stroke (Cochrane Review). In: The Cochrane Library, Issue 4-Oxford: Update Software; 2002.
12. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. low molecular weight heparinoid, ORG 10172 (danaparoid) and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998;279:1265-72.
13. Bath P, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, et al. Tinzaparin in acute ischemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001;358:702-10.
14. Saxena R, Lewis S, Berge E, Sandercock P, Koudstaal P. Risk of early death and recurrent stroke and effect of heparin in 3 169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001;32:2333-7.
15. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low-molecular-weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: a double blind randomised study. Lancet 2000;355:1205-10.
16. Algra A, De Schryver ELLM, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral antociagulation versus antiplatelet therapy for preventing further vascular events after transient attack or minor stroke of presumed arterial origin (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software; 2002.
17. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
18. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033-41.
19. PATS Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J 1995;108:710-7.
20. Di Mascio R, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc Dis 2000;10:85-92.
21. Heart Protection Study Collaboration Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
22. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.